Kenvue FY26 Q2 diluted EPS rises 9% to $0.24; net sales increase 3% vs year earlier to $3.96 billion
PUBT · 1d ago
Share
Listen to the news
- Kenvue posted fiscal Q2 net income of $456 million, lifting diluted EPS 9% to $0.24 versus the prior-year quarter.
- Net sales rose 3% to $3.96 billion; organic sales increased 1.6%, including 0.9% value realization and 0.7% volume growth.
- Gross profit margin narrowed 0.7 percentage points to 58.2%, pressured by inflation and tariffs despite productivity gains.
- CEO Kirk Perry said the transformation is on track as Kenvue works toward closing its Kimberly-Clark deal in Q4 2026.
- FDA cleared Tylenol with Naproxen, an OTC acetaminophen-naproxen combination with three-year exclusivity, expected to reach major U.S. retailers soon.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kenvue Inc. published the original content used to generate this news brief on August 06, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved